PMID- 37047198
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230720
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 7
DP  - 2023 Mar 25
TI  - Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on 
      Post-Traumatic Brain Injuries.
LID - 10.3390/ijms24076219 [doi]
LID - 6219
AB  - Traumatic Brain Injury (TBI) is a primary cause of cerebrovascular and 
      neurological disorders worldwide. The current scientific researchers believe that 
      premorbid conditions such as tobacco smoking (TS) can exacerbate post-TBI brain 
      injury and negatively affect recovery. This is related to vascular endothelial 
      dysfunction resulting from the exposure to TS-released reactive oxygen species 
      (ROS), nicotine, and oxidative stress (OS) stimuli impacting the blood-brain 
      barrier (BBB) endothelium. Interestingly, these pathogenic modulators of BBB 
      impairment are similar to those associated with hyperglycemia. Antidiabetic drugs 
      such as metformin (MF) and rosiglitazone (RSG) were shown to prevent/reduce BBB 
      damage promoted by chronic TS exposure. Thus, using in vivo approaches, we 
      evaluated the effectiveness of post-TBI treatment with MF or RSG to reduce the 
      TS-enhancement of BBB damage and brain injury after TBI. For this purpose, we 
      employed an in vivo weight-drop TBI model using male C57BL/6J mice chronically 
      exposed to TS with and without post-traumatic treatment with MF or RSG. Our 
      results revealed that these antidiabetic drugs counteracted TS-promoted 
      downregulation of nuclear factor erythroid 2-related factor 2 (NRF2) expression 
      and concomitantly dampened TS-enhanced OS, inflammation, and loss of BBB 
      integrity following TBI. In conclusion, our findings suggest that MF and RSG 
      could reduce the harmful impact of chronic smoking on post-traumatic brain 
      injuries.
FAU - Sivandzade, Farzane
AU  - Sivandzade F
AUID- ORCID: 0000-0001-8649-3712
AD  - Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
AD  - Department of Foundation Medical Studies, Oakland University William Beaumont 
      School of Medicine, Rochester, MI 48309, USA.
FAU - Alqahtani, Faleh
AU  - Alqahtani F
AUID- ORCID: 0000-0003-3924-593X
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, Riyadh 11362, Saudi Arabia.
FAU - Dhaibar, Hemangini
AU  - Dhaibar H
AUID- ORCID: 0000-0002-4120-4910
AD  - Department of Molecular and Cellular Physiology, Louisiana State University 
      Health Shreveport, Shreveport, LA 71103, USA.
FAU - Cruz-Topete, Diana
AU  - Cruz-Topete D
AD  - Department of Molecular and Cellular Physiology, Louisiana State University 
      Health Shreveport, Shreveport, LA 71103, USA.
FAU - Cucullo, Luca
AU  - Cucullo L
AUID- ORCID: 0000-0002-2827-7162
AD  - Department of Foundation Medical Studies, Oakland University William Beaumont 
      School of Medicine, Rochester, MI 48309, USA.
LA  - eng
GR  - 1R01-NS117906/NS/NINDS NIH HHS/United States
GR  - 1R01-DA049737/DA/NIDA NIH HHS/United States
GR  - 2R01-DA029121/DA/NIDA NIH HHS/United States
GR  - P20 GM121307/GM/NIGMS NIH HHS/United States
GR  - K01 HL144882/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20230325
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Hypoglycemic Agents)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Mice
MH  - Animals
MH  - Male
MH  - Hypoglycemic Agents/pharmacology/therapeutic use/metabolism
MH  - Mice, Inbred C57BL
MH  - Blood-Brain Barrier/metabolism
MH  - Tobacco Smoking
MH  - Rosiglitazone/pharmacology
MH  - *Metformin/therapeutic use
MH  - *Brain Injuries/drug therapy/etiology/pathology
MH  - *Brain Injuries, Traumatic/complications/drug therapy/metabolism
PMC - PMC10093862
OTO - NOTNLM
OT  - blood-brain barrier
OT  - metformin
OT  - oxidative stress
OT  - rosiglitazone
OT  - smoking
OT  - traumatic brain injury
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:41
PMCR- 2023/03/25
CRDT- 2023/04/13 01:10
PHST- 2023/03/04 00:00 [received]
PHST- 2023/03/18 00:00 [revised]
PHST- 2023/03/22 00:00 [accepted]
PHST- 2023/04/14 06:41 [medline]
PHST- 2023/04/13 01:10 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/03/25 00:00 [pmc-release]
AID - ijms24076219 [pii]
AID - ijms-24-06219 [pii]
AID - 10.3390/ijms24076219 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Mar 25;24(7):6219. doi: 10.3390/ijms24076219.